Quantcast
Last updated on April 17, 2014 at 14:44 EDT

Latest genotype Stories

2011-11-14 16:11:00

PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2011. At fiscal year end Pharmasset held $166.5 million in cash and cash equivalents and used $21.7 million of our cash and cash equivalents during the fourth quarter of fiscal...

2011-11-08 11:00:00

SAN FRANCISCO and RIDGEFIELD, Conn., Nov. 8, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from two Phase 2 studies evaluating the combination of the company's protease inhibitor, BI 201335, with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naive genotype-1 (GT1) hepatitis C virus (HCV) patients. The results from the SILEN-C3 and SILEN-C1 studies show that BI 201335 may have the potential to shorten the duration of...

2011-11-07 23:30:00

⢠Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients ⢠Study expanded to include alfa/RBV ineligible or intolerant patients Princeton, NJ (PRWEB) November 07, 2011 Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a ten patient sentinel cohort of an ongoing Phase II study in which treatment with a dual, all-oral...

2011-11-07 10:00:00

SAN FRANCISCO and RIDGEFIELD, Conn., Nov. 7, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a planned interim analysis of a Phase 2b study, SOUND-C2, that showed the combination of two oral direct acting hepatitis C virus (HCV) compounds - the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127 with ribavirin (RBV) - was successful in reducing viral load below the lower limit of quantifiable levels at week 12 (viral response) in...

2011-11-05 08:05:00

SAN FRANCISCO, Nov. 5, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naive patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San...

2011-11-05 08:00:00

HOERSHOLM, Denmark & SAN DIEGO, Nov. 5, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, presents new data from the Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was maintained for more than four weeks beyond the end...

2011-11-04 06:00:00

PRINCETON, N.J., Nov. 4, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) and Bristol-Myers Squibb Company (NYSE: BMY) announced today the addition of four treatment arms to the ongoing Phase IIa trial evaluating the combination of Pharmasset's PSI-7977, a nucleotide polymerase inhibitor, and Bristol-Myers Squibb Company's daclatasvir (BMS-790052), an investigational NS5A replication complex inhibitor, for the treatment of chronic hepatitis C (HCV). This trial is the result of a...

2011-11-02 07:30:00

STOCKHOLM, November 2, 2011 /PRNewswire/ -- TMC435-Based Therapy Significantly Improved Viral Cure Rates in Patients Who Failed Prior Treatment for Hepatitis C - ASPIRE: All TMC435 subgroups achieved substantially higher viral cure rates (SVR24) compared with control group (pegylated interferon and ribavirin alone): 85% vs. 37% in prior relapsers, 75% vs. 9% in prior partial responders and 51% vs. 19% in prior null responders -...

2011-11-01 05:00:00

PRINCETON, N.J., Nov. 1, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy. "After recent discussions with Health Authorities, we are excited to be initiating the first of...

Image 1 - Google Earth Typhoid Maps Reveal Secrets Of Disease Outbreaks
2011-10-17 03:47:34

In the mid-nineteenth century, John Snow mapped cases of cholera in Soho, London, and traced the source of the outbreak to a contaminated water pump. Now, in a twenty-first century equivalent, scientists funded by the Wellcome Trust working in Kathmandu, Nepal, have combined the latest in gene sequencing technology and global positioning system (GPS) case localization to map the spread of typhoid and trace its source. Typhoid fever is caused by two bacteria — Salmonella typhi and...